Geistlich is one of the first companies in the field of regenerative dentistry to receive MDR certification for its collagen product range. This includes the entire product lines of Geistlich Bio-Gide®, Geistlich Fibro-Gide^® and Geistlich Mucograft^®.
The Swiss company is taking a pioneering role in their field with the approval of these products for bone and soft tissue regeneration.

Geistlich has received MDR (Medical Device Regulation) certification from TÜV SÜD Product Service GmbH for its established product lines of Geistlich Bio-Gide^®, Geistlich Fibro-Gide® and Geistlich Mucograft^®, fulfilling the new EU regulations. Despite the increased and more demanding quality and evidence requirements of the MDR, all indications for these products, which include a variety of regenerative procedures, have been confirmed. Doctors can therefore rely on a complete range of collagen products that meet their high standards of quality and therapeutic safety.

Pioneer in medical regeneration, extended range of indications
Geistlich Fibro-Gide^® is the first non-active class III medical device of animal origin to be certified according to MDR by TÜV SÜD Product Service GmbH. The MDR certification for Geistlich Mucograft^®, which is now also approved for indications outside the mouth in the facial area, is particularly pleasing.

Commitment to the highest quality standards and patient safety Diego Gabathuler, CEO, says: “With the MDR certification, long before the official transition period ends, we underline our commitment to the highest quality standards and patient safety, which we share together with doctors.” With its four subsidiaries and numerous sales partners in Europe, Geistlich has been committed to the well-being of patients on the continent for decades and is driving medical regeneration forward.

About Geistlich Pharma AG (Geistlich)
Geistlich is a global leader dedicated to advancing regenerative medicine. Geistlich has been the world market leader in the field of regenerative dentistry for many years. In addition, Geistlich is committed to providing comprehensive support to clinicians in the field of regenerative medicine through scientific research, innovative developments as well as educational programs. Geistlich is a Swiss family-owned company with tradition since 1851.

With 15 subsidiaries and 60 distributors, the company reaches around 90 markets and employs over 800 people.